ImmuPharma regains Lupuzor rights from Cephalon due to Teva merger

21st October 2011 - 5:06 pm

ImmuPharma PLC (LSE:IMM) (“Immupharma” or the “Company” or the “Group”), the specialist discovery and development pharmaceutical company is pleased to announce that following discussions with Cephalon Inc (Cephalon), its licensee for Lupuzor™, it has regained rights to Lupuzor™, due to the acquisition of Cephalon by Teva Pharmaceutical Industries Ltd (Teva).

Share this article